by Vera Lidwina
Negenborn, Danny Aschwin Young-Afat, Rieky Elise Gustina Dikmans, Jan Maerten
Smit, Henri Adolf Hubert Winters, Johan Peter William Don Griot, Johannes
Wilhelmus Rembertus Twisk, Pieter Quinten Ruhé, Marcus Antonius Maria Mureau,
Oren Lapid, Esther Moerman, Adriaan Anne William Martinus van Turnhout, Mathias
Joseph Petrus Franciscus Ritt, Mark-Bram Bouman, Margriet Gezina Mullender
The Lancet Oncology: Volume 19, issue 9,
P1205-1214, September 01, 2018
Taken together with our
previously published findings, one-stage IBBR with ADM does not yield superior
results in terms of patient-reported QOL compared with two-stage IBBR. Risks
for adverse outcomes were significantly higher in the one-stage ADM group. Use
of ADM for one-stage IBBM should be considered on a case-by-case basis.
